Earnings Releases·Nov 12, 2026, 4:11 PM ET

Pliant Therapeutics — Third Quarter 2026 Earnings Summary

Net loss narrowed to $24.4 million for the quarter and $66.8 million for the nine months ended September 30, 2026, compared to $26.3 million and $125.8 million in the prior-year periods, driven by a $2.5 million reduction in general and administrative expenses and the 2025 termination of the bexotegrast IPF program.
The company holds $142.6 million in cash and short-term investments as of September 30, 2026, providing sufficient funding to operate through mid-2028.
The FORTIFY Phase 1a/1b trial for oncology candidate PLN-101095 is enrolling ahead of schedule across NSCLC, ccRCC, and high tumor mutational burden cohorts, with interim data expected in 2027.
Management announced the appointment of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi), while outlining plans to accelerate neuromuscular and cardiomyopathy programs based on emerging preclinical RNAi data.